期刊文献+

老年晚期非小细胞肺癌个体化治疗临床分析 被引量:4

Individualized therapy of advanced non-small cell lung cancer in the elderly
暂未订购
导出
摘要 目的分析老年非小细胞肺癌个体化治疗方式。方法将我院1995年1月至2005年1月收治的有完整资料98例(年龄≥60岁)老年非小细胞肺癌患者分为单药化疗组、铂类为基础的联合化疗和非铂类的联合化疗三组,对其临床资料及治疗效果进行回顾性对照分析。结果单药化疗组21例,铂类为基础的联合化疗64例,非铂类的联合化疗组13例。单药化疗组心、肝、肾等基础疾病合并率(100.0%)明显高于其他两组(P=0.01)。铂类联合化疗组有效率(39.1%)与非铂类联合化疗组(38.5%)差异无显著性,但明显高于单药化疗组(23.8%);但铂类联合化疗组CR(12.5%)明显高于其他两组(P=0.04)。铂类联合化疗组中位生存期(MST)11个月,疾病进展时间(TTP)7个月,1年生存率37.5%,2年生存率18.8%,均显著高于其他两组(P<0.05)。铂类联合化疗组Ⅲ~Ⅳ度副反应发生率及平均每次住院天数(40d)与非铂类联合化疗组差异无显著性(P>0.05),但明显高于单药化疗组(P<0.05)。结论高龄并非化疗禁忌,一般情况良好的老年非小细胞肺癌应行铂类为基础的联合化疗,一般情况较差者,可行单药化疗。 Objective To analyze individualized therapy mode for advanced non-small cell lung cancer(NSCLC) in the elderly. Methods Ninty-eight patients aged≥60 with advanced NSCLC lung cancer admitted to this hospital from Jan 1995 to Jan 2005 were divided into three groups :single agent chemotherapy group, combined chemotherapy based on platinum and combined chemotherapy without platinum. The clinical characteristics and treatment efficacy were reviewed and compared. Results There were 21 cases in the single agent chemotherapy group ,64 cases in the combined chemotherapy based on platinum group, 13 cases in the combined chemotherapy without platinum group. The underlying severe diseases rate( 100% ) in the single agent group was significantly higher than that in the other two groups( P = 0.01 ). The response rate(RR) of combined chemotherapy with platinum group (39.1% ) was not significantly different from the combined chemotherapy without platinum group (38.5%) , but it was significantly higher than that in the single agent chemotherapy group(23.8% ). The complete response rate(CR) of the combined chemotherapy with platinum group ( 12.5 % ) was markedly higher than that of the other two groups (P = 0.04). The median survival time(MST) (11 months),to treatment progress time(TIP) (7 months),one-year survival rate(37.5% ) and 2-year survival rate( 18.8% ) of the combined chemotherapy with platinum group were significantly higher than those of the other two groups ( P 〈 0.05 ). The Ⅲ- Ⅳ-degree side effects and mean hospitalization days each time(40 days)in combined chemotherapy with platinum group had no significant difference from the combined chemotherapy without platinum group (P 〉 0.05 ). Conclusion The elderly advanced NSCLC patients with good general condition can receive combined chemotherapy based on platinum, while the patients with poor general condition can receive single agent chemotherapy.
出处 《中国肿瘤临床与康复》 2008年第1期33-37,共5页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 老年 肺肿瘤/治疗学 个体化 Elderly Lung neoplasms/therapy Individualized chemotherapy
  • 相关文献

参考文献19

  • 1Creenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics [J]. CA Cancer J Clin,2001,51:15-36.
  • 2Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States:a national cancer data base report[J]. Cancer,1999,86:1867-1876.
  • 3Gridelli C. The ELVIS trial : a phase Ⅲ study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study[J]. Oncologist,2001,6(Suppl 1 ) :S4-S7.
  • 4Hotta K, Ueoka H, Kiura K. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer[J]. Lung Cancer,2004,46:61-76.
  • 5Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer:a multicenter phase Ⅱ study[J]. Lung Cancer,2000,27:75-80.
  • 6Hainsworth JD, Burris HA 3rd, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma: a Minnie Pearl Cancer Network Phase Ⅱ Trial [ J ]. Cancer,2000,89 : 328-333.
  • 7Fidias P,Supko JG, Martins R, et al. A phase Ⅱ study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer[ J]. Clin Cancer Res,2001,7:3942-3949.
  • 8Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer:the Muhicenter Italian Lung Cancer in the Elderly Study(MILES) phase Ⅲ randomized trial[J]. J Natl Cancer Inst,2003 ,95 :362-372.
  • 9Comella P, frasci G, Carnicelli p, et al. Gemcitabine with either paclitaxel or vinorebine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients[ J]. Br J Cancer ,2004,91 ( 3 ) :489-497.
  • 10Mainwaring MG, Hainsworth JD, Spigel DR, et al. Weekly docetaxel verus weekly docetaxel/gemcitabine as first-line therapy for patients who are elderly or with poor performance status (PS) or with serious comorbidities with advanced non-small cell lung cancer (NSCLC) :Interim safety analysis of a Minnie Pearl Cancer Research Network phase Ⅲ trial [ J ]. J Clin Oneol, 2005,23 (16S) :658s.

二级参考文献5

  • 1Non-Small Cell Lung Cancer Co-operative Group. Chemotherapy in non-small cell lung cancer:a meta-analysis using up-dated data on individual patients form 52 randomized trials[J]. Br Med J,1995(31):899-909.
  • 2Gridelli C, Perrone F, Cigolari S, et al. The MILES (multicenter italian lung cancer in the elderly study phase Ⅲ trial):gemcitabine+vinorelbine vs vinorelbine vs gemcitabine in elderly advanced NSCLC patients [J]. ASCO,2001,(20):308a.abstract.
  • 3Hirsh V, Langleben A, Ayoub J, et al. Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic non-small cell lung carcinoma. A phase Ⅱ multicenter trial[J]. Cancer 2001,92(4):830-835.
  • 4Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer:Results of a European multicenter trial including 612 patients[J]. J Clin Oncol,1994,12(2):360-367.
  • 5张湘茹,孙燕,孔维红,周生余,冯奉仪.去甲长春花碱加顺铂治疗晚期非小细胞肺癌42例[J].中华肿瘤杂志,1998,20(1):60-62. 被引量:527

共引文献5

同被引文献26

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部